Evidence map›Paper›PMID 42860380›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

The effects of improved access to diabetes medications on risk of Alzheimer's disease and related dementias.

Douglas Barthold, Julie Zissimopoulos, Anirban Basu, Bryan Tysinger

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Douglas BartholdThe Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Julie ZissimopoulosPrice School of Public Policy, Leonard D. Schaeffer Institute for Public Policy and Government, University of Southern California, Los Angeles, California, USA.
Anirban BasuThe Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Bryan TysingerPrice School of Public Policy, Leonard D. Schaeffer Institute for Public Policy and Government, University of Southern California, Los Angeles, California, USA.

Funding

USC Resource Center for Minority Aging Research (US-RCMAR)P30AG043073 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Mireille Jacobson · 2012 to 2026
$10.1M
Use and Impact of Novel and Repurposed Therapeutics for Alzheimer's Disease and Related Dementia in the United StatesR33AG081811 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DAVID ALAN BENNETT, JULIE M ZISSIMOPOULOS · 2025 to 2026
$1.2M
Long-term effects of today's medical care access policies on the future burden of Alzheimer's disease and related dementiasK01AG071843 · NIA · UNIVERSITY OF WASHINGTON · PI DOUGLAS BARTHOLD · 2022 to 2026
$610k
NIA NIH HHS K01 AG071843NIA NIH HHS P30 AG043073NIA NIH HHS R33 AG081811
6 · The paper itself

Abstract

introductionDiabetes is associated with elevated risk of Alzheimer's disease and related dementias (ADRD). Disease management with pharmaceutical therapies may mitigate this increased risk, but access and use of diabetes therapies are limited, especially for persons at highest risk of ADRD.

methodsUsing 10 years of data on Americans aged 51 and older with diabetes, we employed dynamic microsimulation to analyze the impact of increased utilization of glucagon-like peptide 1 receptor agonists (GLP1s) and sodium-glucose cotransporter-2 inhibitors (SGLT2s) on ADRD incidence.

resultsOver 10 years, utilization of GLP1s and SGLT2s by people with diabetes and HbA1c > 7 could avert 76,000-201,000 ADRD cases. The risk reduction is largest for Black and Hispanic individuals and individuals with HbA1c > 8. DISCUSSION: This study shows that improving diabetes management can lead to large reductions in ADRD risk. Improved adherence and access for those with higher HbA1c and higher risk of ADRD will have the largest benefit.

Indexed as

Alzheimer DiseaseDementiaDiabetes MellitusDiabetes Mellitus, Type 2Health Services AccessibilityHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsAgedFemaleGlucagon-Like Peptide-1 Receptor AgonistsHumansIncidenceMaleMiddle AgedGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitorsaccess to prescription drugsADRDADRD preventionAlzheimer's diseaseAlzheimer's disease and related dementiaschronic disease managementdementiadementia preventiondiabetesdiabetes managementGLP1glucagon‐like peptide 1 receptor agonistsSGLT2sodium‐glucose cotransporter‐2 inhibitors

Identifiers

PMID42860380
PMCPMC13655229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.